Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.65 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.54 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7582536 | 0.93 | PARP1 (0.62) | PARP1TRPM2PARP10PARP11HDAC1 | |
| SCHEMBL9196870 | 0.87 | PARP1 (0.66) | PARP1TRPM2PARP10PARP11HDAC1 | |
| SCHEMBL7581574 | 0.87 | PARP1 (0.58) | PARP1TRPM2PARP10PARP11HDAC1 | |
| SCHEMBL4717294 | 0.86 | PARP1 (0.65) | PARP1TRPM2PARP10PARP11HDAC1 | |
| SCHEMBL9196993 | 0.81 | PARP1 (0.59) | PARP1TRPM2PARP10PARP11HDAC1 | |
| SCHEMBL10576365 | 0.81 | PARP1 (0.65) | PARP1TRPM2PARP10PARP11 | |
| SCHEMBL7587804 | 0.80 | TRPM2 (0.93) | PARP1TRPM2CYP2C19 | |
| SCHEMBL12969185 | 0.80 | CYP1A2 (0.44) | PARP1TRPM2CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL437787 | 0.79 | PARP1 (0.63) | PARP1TRPM2PARP10PARP11CYP19A1 | |
| SCHEMBL29688148 | 0.79 | PARP1 (0.63) | PARP1TRPM2PARP10PARP11CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | claimed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | claimed |
| US-6348475-B1 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | PARP1 2/4885TRPM2 4208/4885PARP10 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.